Kevad Bio

Argobio, GeneCode and University of Helsinki partner to develop a new class of small molecule activating the GFRa1/RET complex for the treatment of Parkinson's disease and other indications

• Scientific founder : Prof. Mart Saarma, Professor and Research Director of the Institute of Biotechnology, HI-LIFE, University of Helsinki, Finland
   
• Small molecules with drug-like properties producing neurotrophic and neuroprotective effects on human dopaminergic neurons
   
• Disease modification and efficacy on both motor and non-motor symptoms
   
• Argobio will fund the development of this innovative project up to €3 million and incorporate a new specialized biotechnology company
   
• Additionally secured European grant of €2 million
   
• Collaborative ecosystem